

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
17 February 2005 (17.02.2005)

PCT

(10) International Publication Number  
WO 2005/014648 A1

(51) International Patent Classification<sup>7</sup>: C07K 14/81, (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(21) International Application Number: PCT/EP2004/009043

(22) International Filing Date: 12 August 2004 (12.08.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data: 60/494,097 12 August 2003 (12.08.2003) US

(71) Applicant (for all designated States except US): OCTAPHARMA AG [CH/CH]; Seidenstrasse 2, CH-8853 Lachen (CH).

(72) Inventors; and

(75) Inventors/Applicants (for US only): SCHULZ, Petra [AT/AT]; Oberlaaer Strasse 235, A-1100 Vienna (AT). RÖMISCH, Jürgen [DE/AT]; Laxenburger Strasse 152/2/6, A-2331 Vösendorf (AT).


(74) Agents: MEYERS, Hans-Wilhelm et al.; P.O. Box 10 22 41, 50462 Cologne (DE).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PROCESS FOR PREPARING AN ALPHA-1-ANTITRYPSIN SOLUTION



(57) Abstract: A process for preparing A1AT from A1AT-containing solutions, comprising the following steps: (a) subjecting an A1AT-containing solution to ion-exchange chromatography; (b) adding detergents and optionally a solvent for inactivating lipid-enveloped viruses; (c) followed by increasing the salt concentration to salt out the detergents. A1AT having a purity of > 90% with an activity of  $\geq$  0.8 PEU/mg in its active form.